OMER
HEALTHCAREOmeros Corporation
$14.83+0.06 (+0.41%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving OMER Today?
No stock-specific AI insight has been generated for OMER yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$2.95$17.65
$14.83
Fundamentals
Market Cap$1.1B
P/E Ratio—
EPS$-0.08
Dividend Yield—
Dividend / Share—
ROE-5.8%
Profit Margin—
Debt / Equity—
Trading
Volume540K
Avg Volume (10D)—
Shares Outstanding72.2M
OMER News
20 articles- Zacks Industry Outlook Highlights Phibro Animal Health, BioLife Solutions, Omeros and BrainswayYahoo Finance·Apr 28, 2026
- Here's Why Omeros (OMER) is a Great Momentum Stock to BuyYahoo Finance·Apr 27, 2026
- Wall Street Analysts Believe Omeros (OMER) Could Rally 222.76%: Here's is How to TradeYahoo Finance·Apr 27, 2026
- 4 Medical Product Stocks to Buy From a Challenging IndustryYahoo Finance·Apr 27, 2026
- Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical OfficerGlobeNewswire Inc.·Apr 20, 2026
- CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug)Yahoo Finance·Apr 16, 2026
- Does Omeros (OMER) Have the Potential to Rally 266.67% as Wall Street Analysts Expect?Yahoo Finance·Apr 10, 2026
- Omeros Corporation Q4 2025 Earnings Call SummaryMoby·Apr 1, 2026
- Omeros Corp (OMER) Q4 2025 Earnings Call Highlights: A Turnaround with Strategic Deals and FDA ...Yahoo Finance·Apr 1, 2026
- Omeros Q4 Earnings Call HighlightsMarketbeat·Mar 31, 2026
- Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial ResultsYahoo Finance·Mar 31, 2026
- Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026Yahoo Finance·Mar 26, 2026
- Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA TreatmentYahoo Finance·Mar 21, 2026
- Omeros Announces Successful Primate Study in OncotoX-AML™ Drug ProgramYahoo Finance·Feb 17, 2026
- Omeros Corporation's (NASDAQ:OMER) market cap dropped US$60m last week; individual investors who hold 50% were hit as were institutionsYahoo Finance·Feb 4, 2026
- Omeros Announces First Commercial Sales of YARTEMLEA®Yahoo Finance·Jan 27, 2026
- Catalyst Monitor Report: Q1 2026 Outlook: Regulatory Approvals and Late-Stage Trials Signal Strong Pipeline Momentum Across Key Therapeutic AreasYahoo Finance·Jan 20, 2026
- Exchange-Traded Funds, Equity Futures Higher Ahead of First Trading Day of 2026Yahoo Finance·Jan 2, 2026
- Omeros Gets FDA Approval for YARTEMLEA as First Therapy for TA-TMAYahoo Finance·Dec 29, 2025
- Omeros Announces New Date for YARTEMLEA® Approval Conference CallYahoo Finance·Dec 26, 2025
All 20 articles loaded
Price Data
Open$14.77
Previous Close$14.77
Day High$14.92
Day Low$14.63
52 Week High$17.65
52 Week Low$2.95
52-Week Range
$2.95$17.65
$14.83
Fundamentals
Market Cap$1.1B
P/E Ratio—
EPS$-0.08
Dividend Yield—
Dividend / Share—
ROE-5.8%
Profit Margin—
Debt / Equity—
Trading
Volume540K
Avg Volume (10D)—
Shares Outstanding72.2M
About Omeros Corporation
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and markets protein and small molecule therapies, and orphan indications targeting inflammation, complement-mediated diseases, central nervous system (CNS) disorders, and system-related diseases. immunological. The company is headquartered in Seattle, Washington.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—